340 related articles for article (PubMed ID: 111368)
1. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
Wijngaards G
Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
3. Human articular cartilage contains an inhibitor of plasminogen activator.
Yamada H; Stephens RW; Nakagawa T; McNicol D
J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
[TBL] [Abstract][Full Text] [Related]
4. Separation of plasminogen activators from human uterine tissue and a comparison with activators from human urine and porcine tissue.
Kok P
Thromb Haemost; 1979 Jun; 41(4):718-33. PubMed ID: 113901
[TBL] [Abstract][Full Text] [Related]
5. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
7. Isolation of peptides with anti-urokinase activity from the human placenta.
Uszynski M
Thromb Haemost; 1980 Feb; 42(5):1411-6. PubMed ID: 6768150
[TBL] [Abstract][Full Text] [Related]
8. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.
Gross JL; Behrens DL; Mullins DE; Kornblith PL; Dexter DL
Cancer Res; 1988 Jan; 48(2):291-6. PubMed ID: 3121170
[TBL] [Abstract][Full Text] [Related]
11. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators and urokinase inhibitors in the lungs of foetuses and newborns.
Uszynska-Folejewska R
Anaesth Resusc Intensive Ther; 1976; 4(1):41-5. PubMed ID: 970616
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of tissue activator and urokinase by human plasma.
Walker JE; Ogston D
Thromb Haemost; 1982 Jun; 47(3):265-8. PubMed ID: 6180497
[TBL] [Abstract][Full Text] [Related]
14. Immunological characterization of plasminogen activator activities in human tissues and body fluids.
Rijken DC; Wijngaards G; Welbergen J
J Lab Clin Med; 1981 Apr; 97(4):477-86. PubMed ID: 6782183
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
Félez J; Rueda F
Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
[No Abstract] [Full Text] [Related]
16. Proceedings: Inhibitors interfering with the quantitative estimation of tissue plasminogen activator.
Wijngaards G; Potjer AT
Thromb Diath Haemorrh; 1975 Sep; 34(1):320. PubMed ID: 810912
[No Abstract] [Full Text] [Related]
17. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator.
Astedt B; Lecander I; Brodin T; Lundblad A; Löw K
Thromb Haemost; 1985 Feb; 53(1):122-5. PubMed ID: 3922076
[TBL] [Abstract][Full Text] [Related]
18. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
19. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
